Why Ironwood Pharmaceuticals, Inc.’s (IRWD) Stock Is Down 4.28% (2024)

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ironwood Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Ironwood Pharmaceuticals, Inc.’s stock price such as:

Before we jump into Ironwood Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Want to learn more about Ironwood Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ironwood Pharmaceuticals, Inc..

As of May 22, 2024, 4:00 PM, CST, Ironwood Pharmaceuticals, Inc.’s stock price was $6.49.

Ironwood Pharmaceuticals, Inc. is down 4.28% from its previous closing price of $6.78.

During the last market session, Ironwood Pharmaceuticals, Inc.’s stock traded between $6.37 and $6.81. Currently, there are 157.70 million shares of Ironwood Pharmaceuticals, Inc. stock available for purchase.

Unfortunately, Ironwood Pharmaceuticals, Inc.’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Ironwood Pharmaceuticals, Inc.’s (IRWD) price is currently down 16.26% so far this month.

During the month of May, Ironwood Pharmaceuticals, Inc.’s stock price has reached a high of $8.45 and a low of $6.21.

Over the last year, Ironwood Pharmaceuticals, Inc. has hit prices as high as $15.70 and as low as $6.21. Year to date, Ironwood Pharmaceuticals, Inc.’s stock is down 47.62%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 21, 2024, there were 3 analysts who downgraded Ironwood Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Ironwood Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ironwood Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ironwood Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ironwood Pharmaceuticals, Inc. (IRWD) by visiting AAII Stock Evaluator.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 21, 2024, Ironwood Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -18.52%, which translates to a Momentum Score of 18 and is considered to be Very Weak.

Want to learn more about how Ironwood Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

As of May 22, 2024, Ironwood Pharmaceuticals, Inc.’s stock price is $6.49, which is down 4.28% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ironwood Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.